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to previous treatment may not reap the beneﬁt of survival improve-
ment because they were already in a terminal stage at the time of stent 
placement. Interventional pulmonologists should be aware of the dis-
couraging prognosis and the risk of impediments for terminal patients, 
especially in cases of multiple stent placements. 
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Background: Lung cancer accounts for more deaths than breast, pros-
tate and colon cancers combined. Prognosis and survival depend on the 
stage of disease, and since more than two thirds of patients with lung 
cancer have mediastinal lymph node or distant metastases at presenta-
tion, it is not surprising that cure rate remains dismal at 15%.
Aim: To determine if early detection and intervention for central air-
way lung cancer could impact outcome of patients at risk.
Methods: All current or former smokers with ≥1 aerodigestive cancers 
were recruited for the program beginning January 1996 to December 
2005 and prospectively followed till December 2006. Autoﬂuores-
cence bronchoscopy was performed with LIFE® (Xilix, BC, Richmond 
Canada) every 3-6 months, and where indicated, bronchoscopic treat-
ment was applied as an alternative to surgery or to enable less exten-
sive resection whenever feasible. Values are presented as median and 
range, and lung cancer related mortality is calculated by Kaplan Meier 
method.
Results: There were 228 individuals, 190 males with median age 69 
years (range, 62-75). They smoked 40 median pack years (range, 34-
50), and 70% had COPD with median FEV1 % predicted 53% (range, 
39-70). Follow-up was 40 months (range, 22-79), and the indications 
were: surveillance after lung cancer surgery in 94 patients (41%); 
previous ENT cancer in 32 (14%); suspected occult lung cancer in 92 
(41%); and known lung cancer in 10 (4%). There were 111 patients 
with one lung cancer, and 99 with 2 or more lung cancers. A total of 
217 new lung cancers were diagnosed: AF detected 181 and 36 by CT. 
Of the 92 patients with intraluminal squamous cell cancers (ISCC), 12 
(13%) underwent surgery with one requiring post-operative radio-
therapy (RT), 10 (11%) had RT alone and one (1%) received concurrent 
chemoradiotherapy. The remaining 69 patients (75%) had their multiple 
ISCC treated with endobronchial electrosurgery or cryotherapy. At the 
end of our study period, 123 individuals (54%) were alive, and 105 
(46%) deceased. Lung cancer-related mortality (Fig 1) was 21% (6.3%/ 
year) and the all cause mortality was 46%. 
Conclusions: Our results validate efforts towards early detection and 
intervention for this high risk group with ≥ 1 cancers. Bronchoscopic 
treatment could emerge as an effective alternative to surgery for early 
detected ISCC. 
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Background: The bronchial mucosa is the tissue ﬁrst exposed to dif-
ferent cancerogenes including tobacco smoke. Pathologic changes in 
the mucosa evolve from basal cell hyperplasia to epithelial dysplasia 
and cancer in situ. This process causes subtle changes in chemical 
composition and blood supply of mucosa and thickness of the basal 
membrane. This is why the processing of autoﬂuorescent signal from 
the bronchial mucosal surface is gaining increasing interest recently. 
Signiﬁcant weakness of commercial autoﬂuorescence systems is low 
speciﬁcity caused by decreased ﬂuorescence of the mucosa changed by 
chronic inﬂammation or other non-malignant endobronchial conditions. 
Methods: In order to increase speciﬁcity of the auto ﬂuorescent device 
we have tested system utilizing spectroscopic point monitoring of sus-
picious endobronchial locations. Every AFB positive location has been 
measured by this system and than visualized by NBI system. Evaluated 
group consisted of 30 patients with autoﬂuorescence positive endobron-
chial locations. 
Results and Conclusion: We have picked up some typical differences 
in autoﬂuorescence spectra’s between malignant and non-malignant 
tissues which are shown in graphs. We have also found that NBI tissue 
characteristics are very useful in discriminating between endobronchial 
